Institution
Tel Aviv University
Education•Tel Aviv, Israel•
About: Tel Aviv University is a education organization based out in Tel Aviv, Israel. It is known for research contribution in the topics: Population & Medicine. The organization has 47791 authors who have published 115959 publications receiving 3904391 citations. The organization is also known as: TAU & Universiṭat Tel-Aviv.
Topics: Population, Medicine, Poison control, Context (language use), Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: GSH status, the biologically relevant chemistry of GSH, the forms in which GSH can be present within the cell, along with the GSH content of cells and the methods for analysis of this substance are discussed.
Abstract: Publisher Summary Glutathione (GSH) is the most important nonprotein thiol in living systems and is of widespread occurrence in the intracellular milieu of animals, plants, and microorganisms GSH was isolated and named by the English biochemist Frederick Gowland Hopkins This chapter discusses GSH status, the biologically relevant chemistry of GSH, the forms in which GSH can be present within the cell, along with the GSH content of cells and the methods for analysis of this substance GSH-related biochemical reactions and the biological roles of GSH are discussed in the chapter The use of perturbations in GSH status as a means for investigating GSH-related phenomena and an analysis of the consequences of perturbation are presented A short summary of genetic lesions related to GSH is also included Like chemically induced perturbations in GSH status, genetic lesions provide valuable insights into the role of GSH in normal functions and processes in cells The chapter concludes with some brief comments about the future of the relationship of GSH status to cellular processes
1,208 citations
••
Yale Cancer Center1, Princess Margaret Cancer Centre2, University of Toronto3, Osaka University4, University of Kansas5, University of Pittsburgh6, Indiana University7, NewYork–Presbyterian Hospital8, Pontifical Catholic University of Chile9, Tel Aviv University10, Sheba Medical Center11, University of California, Los Angeles12, University of Chicago13, Tel Aviv Sourasky Medical Center14, Sanford Health15, University of California, San Francisco16, Memorial Sloan Kettering Cancer Center17, Harvard University18, New Generation University College19, Merck & Co.20, Mayo Clinic21
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Abstract: Importance Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. Objective To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer. Design, Setting, and Participants In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016. Median (range) follow-up was 5.8 (0.5-21.6) months. Intervention Patients received pembrolizumab, 200 mg, intravenously every 3 weeks until disease progression, investigator or patient decision to withdraw, or unacceptable toxic effects. Main Outcomes and Measures Primary end points were objective response rate and safety. Objective response rate was assessed by central radiologic review per Response Evaluation Criteria in Solid Tumors, version 1.1, in all patients and those with programmed cell death 1 ligand 1 (PD-L1)–positive tumors. Expression of PD-L1 was assessed by immunohistochemistry. Secondary end points included response duration. Results Of 259 patients enrolled, most were male (198 [76.4%]) and white (200 [77.2%]); median (range) age was 62 (24-89) years. Objective response rate was 11.6% (95% CI, 8.0%-16.1%; 30 of 259 patients), with complete response in 2.3% (95% CI, 0.9%-5.0%; 6 of 259 patients). Median (range) response duration was 8.4 (1.6+ to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). Objective response rate and median (range) response duration were 15.5% (95% CI, 10.1%-22.4%; 23 of 148 patients) and 16.3 (1.6+ to 17.3+) months and 6.4% (95% CI, 2.6%-12.8%; 7 of 109 patients) and 6.9 (2.4 to 7.0+) months in patients with PD-L1–positive and PD-L1–negative tumors, respectively. Forty-six patients (17.8%) experienced 1 or more grade 3 to 5 treatment-related adverse events. Two patients (0.8%) discontinued because of treatment-related adverse events, and 2 deaths were considered related to treatment. Conclusions and Relevance Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment. Durable responses were observed in patients with PD-L1–positive and PD-L1–negative tumors. Further study of pembrolizumab for this group of patients is warranted. Trial Registration clinicaltrials.gov Identifier: NCT02335411
1,203 citations
••
TL;DR: It is shown that generated medical images can be used for synthetic data augmentation, and improve the performance of CNN for medical image classification, and generalize to other medical classification applications and thus support radiologists’ efforts to improve diagnosis.
1,202 citations
••
1,199 citations
••
TL;DR: It is indicated that healthcare staff involved in the care of COVID-19 positive patients, and individuals considering themselves at risk of disease, were more likely to self-report acquiescence to CO VID-19 vaccination if and when available, and parents, nurses, and medical workers not caring for SARS-CoV-2 positive patients expressed higher levels of vaccine hesitancy.
Abstract: Vaccine hesitancy remains a barrier to full population inoculation against highly infectious diseases. Coincident with the rapid developments of COVID-19 vaccines globally, concerns about the safety of such a vaccine could contribute to vaccine hesitancy. We analyzed 1941 anonymous questionnaires completed by healthcare workers and members of the general Israeli population, regarding acceptance of a potential COVID-19 vaccine. Our results indicate that healthcare staff involved in the care of COVID-19 positive patients, and individuals considering themselves at risk of disease, were more likely to self-report acquiescence to COVID-19 vaccination if and when available. In contrast, parents, nurses, and medical workers not caring for SARS-CoV-2 positive patients expressed higher levels of vaccine hesitancy. Interventional educational campaigns targeted towards populations at risk of vaccine hesitancy are therefore urgently needed to combat misinformation and avoid low inoculation rates.
1,188 citations
Authors
Showing all 48197 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jing Wang | 184 | 4046 | 202769 |
Aviv Regev | 163 | 640 | 133857 |
Itamar Willner | 143 | 927 | 76316 |
M. Morii | 134 | 1664 | 102074 |
Halina Abramowicz | 134 | 1192 | 89294 |
Joost J. Oppenheim | 130 | 454 | 59601 |
Gideon Bella | 129 | 1301 | 87905 |
Avishay Gal-Yam | 129 | 795 | 56382 |
Erez Etzion | 129 | 1216 | 85577 |
Allen Mincer | 129 | 1040 | 80059 |
Abner Soffer | 129 | 1028 | 82149 |
Gideon Koren | 129 | 1994 | 81718 |
Alex Zunger | 128 | 826 | 78798 |
Odette Benary | 128 | 844 | 74238 |
Gideon Alexander | 128 | 1201 | 81555 |